Yttrium Y 90 daclizumab

{
  "id": "MLC-T-ONC-017630",
  "term": "Yttrium Y 90 daclizumab",
  "field": "Oncology and biomedicine",
  "definition": "A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity. Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes. As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor.",
  "synonyms": [
    "Y90 MOAB anti-Tac",
    "Y90 daclizumab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/yttrium-y-90-daclizumab/"
}